Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498185 | 0.94 | TSHR (0.49) | RAB9AHPGDKDM4EPKMTSHR | |
| SCHEMBL6508701 | 0.85 | KDM4E (0.50) | KDM4ETSHRHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6506745 | 0.85 | ATM (0.48) | RAB9AHPGDKDM4EPKMTSHR | |
| SCHEMBL6503729 | 0.83 | EPHX2 (0.58) | RAB9AKDM4ETSHRHSD17B10ALDH1A1 | |
| SCHEMBL6500610 | 0.83 | GAA (0.59) | HPGDKDM4ETSHRHSD17B10MEN1 | |
| SCHEMBL6499688 | 0.83 | CYP1A2 (0.56) | RAB9AHPGDKDM4ETSHRHSD17B10 | |
| SCHEMBL6504830 | 0.82 | BCHE (0.54) | KDM4ETSHRHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6498720 | 0.81 | BCHE (0.59) | TSHRHSD17B10KMT2APOLBBCHE | |
| SCHEMBL6507792 | 0.79 | MTNR1A (0.51) | KDM4ETSHRHSD17B10MEN1KMT2A | |
| SCHEMBL6505391 | 0.79 | TSHR (0.52) | KDM4ETSHRHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | RAB9A 3180/4885HPGD 761/4885KDM4E 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.